Association between diabetes medication and less severe cases of COVID-19

Credit: Pixabay/CC0 Public Domain

Published in PLOS ONE, a study led by the University of Minnesota Medical School studied adults with type 2 diabetes who were taking metformin, a commonly prescribed diabetes medication. Researchers found an association with less severe cases of COVID-19 for those prescribed metformin. These findings were part of an observational study that analyzed electronic medical charts and compared adults who were taking either metformin, a sulfonylurea or a DPP-4 inhibitor.

"This study continues to provide justification for further research on for COVID-19. We're fortunate to have biostatisticians and informatics experts in our Clinical and Translational Science Institute who are exceptional in observational analyses," said Carolyn Bramante, MD, an assistant professor at the University of Minnesota Medical School and an internist and pediatrician with M Health Fairview.

The study found that among adults with type 2 diabetes who were taking one oral medication for their condition, those taking metformin had a 45% lower risk of needing a or dying from COVID-19 than similar individuals who were not taking metformin. Of the similar analyses that have been done, this study used a database large enough to allow a rigorous study of the utilization and effect of these drugs in a larger, well-defined population. The research team collaborated with national experts in pharmaco-epidemiology.

These findings add to the growing body of data that suggests metformin reduces the severity of COVID-19. Dr. Bramante led the COVID-OUT trial, which published findings earlier this year that showed metformin lowers the odds of emergency department visits, hospitalizations or death due to COVID-19.

Some of this most recent data includes test-tube experiments in which metformin stopped the virus from multiplying. Researchers say metformin is safe, inexpensive and widely available, thus more are warranted.

More information: Carolyn T. Bramante et al, Diabetes medications and associations with Covid-19 outcomes in the N3C database: A national retrospective cohort study, PLOS ONE (2022). DOI: 10.1371/journal.pone.0271574

Journal information: PLoS ONE

Citation: Association between diabetes medication and less severe cases of COVID-19 (2022, November 18) retrieved 1 December 2023 from
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Explore further

Trial suggests metformin effective at reducing odds of serious outcomes for COVID-19 patients seeking early treatment


Feedback to editors